Beigene Mahogany
A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Rituximab or Obinutuzumab Versus Lenalidomide plus Rituximab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL). The MAHOGANY trial
Description: This trial assesses the effectiveness of Zanubrutinib Plus Rituximab or Obinutuzumab combination v's Lenalidomide plus Rituximab combination in patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Study Phase: Phase 3
Principal Investigator: Prof Elisabeth Vandenberghe
Further information
